YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 11.9
(1.02%)
HKD 11.9
(1.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.8 Billion CNY | -17.37% |
| 2022 | 5.81 Billion CNY | 28.73% |
| 2021 | 4.52 Billion CNY | 1.42% |
| 2020 | 4.45 Billion CNY | -15.72% |
| 2019 | 5.28 Billion CNY | 499.67% |
| 2018 | 882.01 Million CNY | 23.29% |
| 2017 | 715.38 Million CNY | 91.64% |
| 2016 | 373.3 Million CNY | -14.1% |
| 2015 | 434.56 Million CNY | -35.36% |
| 2014 | 672.27 Million CNY | -42.99% |
| 2013 | 1.17 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.82 Billion CNY | -20.38% |
| 2023 Q2 | 6.35 Billion CNY | 9.11% |
| 2023 Q4 | 4.8 Billion CNY | -24.27% |
| 2023 FY | 4.8 Billion CNY | -17.37% |
| 2022 Q2 | 4.82 Billion CNY | 6.74% |
| 2022 FY | 5.81 Billion CNY | 28.73% |
| 2022 Q4 | 5.81 Billion CNY | 20.61% |
| 2021 Q4 | 4.52 Billion CNY | 4.72% |
| 2021 Q2 | 4.31 Billion CNY | -3.15% |
| 2021 FY | 4.52 Billion CNY | 1.42% |
| 2020 FY | 4.45 Billion CNY | -15.72% |
| 2020 Q2 | 5.48 Billion CNY | 3.72% |
| 2020 Q4 | 4.45 Billion CNY | -18.75% |
| 2019 FY | 5.28 Billion CNY | 499.67% |
| 2019 Q2 | 4.86 Billion CNY | 451.66% |
| 2019 Q4 | 5.28 Billion CNY | 8.7% |
| 2018 Q4 | 882.01 Million CNY | -12.9% |
| 2018 Q2 | 1.01 Billion CNY | 41.54% |
| 2018 FY | 882.01 Million CNY | 23.29% |
| 2017 Q2 | 580.78 Million CNY | 55.58% |
| 2017 FY | 715.38 Million CNY | 91.64% |
| 2017 Q4 | 715.38 Million CNY | 23.18% |
| 2016 FY | 373.3 Million CNY | -14.1% |
| 2016 Q2 | 489.7 Million CNY | 12.69% |
| 2016 Q4 | 373.3 Million CNY | -23.77% |
| 2015 Q2 | 679.58 Million CNY | 1.09% |
| 2015 Q4 | 434.56 Million CNY | -36.05% |
| 2015 FY | 434.56 Million CNY | -35.36% |
| 2014 FY | 672.27 Million CNY | -42.99% |
| 2014 Q4 | 672.27 Million CNY | 0.0% |
| 2013 FY | 1.17 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -3279.778% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 33.624% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -2721.959% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -577.628% |
| Qianhai Health Holdings Limited | 94 Million HKD | -5015.598% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -417.039% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -432.077% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -622.707% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -597.283% |
| SSY Group Limited | 4.49 Billion HKD | -7.007% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -1211.187% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -340.976% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 97.145% |